代谢综合征不影响替拉珠单抗长期疗效与安全性
基于reSURFACE 1和2两项3期随机对照试验的事后分析,评估替拉珠单抗在伴或不伴代谢综合征银屑病患者中的长期疗效、药物存活和安全性。结果显示,连续接受替拉珠单抗100mg或200mg治疗的患者中,伴与不伴代谢综合征者在第52周及第148周的PASI 75/90/100应答率总体相当,安全性特征无差异。
要点
- 代谢综合征状态不影响替拉珠单抗长期PASI应答。
- 替拉珠单抗安全性在伴或不伴代谢综合征患者中无差异。
- 研究为事后分析,样本量较小,解释需谨慎。
核心结论
- 长期替拉珠单抗在伴与不伴代谢综合征的银屑病患者中疗效和安全性相当。
研究设计与样本
- reSURFACE 1和2两项3期双盲随机对照试验及其扩展研究的事后分析,评估长达3年疗效数据和5年安全性数据。
- 连续接受替拉珠单抗100mg的患者338例(reSURFACE 1/2:124/214),200mg患者307例(147/160)。
- 100mg组中26/44例(21%/21%)符合代谢综合征标准,200mg组中34/30例(23%/19%)符合。
主要发现
- 第52周时,伴与不伴代谢综合征患者达到PASI 75的比例总体相当:100mg组分别为85%/86% vs 86%/94%,200mg组分别为76%/87% vs 76%/87%。
- PASI 90和PASI 100应答者的结果与PASI 75相似,持续至第148周。
- 替拉珠单抗的安全性特征不因代谢综合征状态而改变。
临床怎么用
- 对于伴代谢综合征的银屑病患者,替拉珠单抗的长期疗效和安全性预期与不伴代谢综合征者相似。
局限性
- 样本量较小,且为事后分析,限制了解释。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Data for the effect of metabolic syndrome (MetS) on the efficacy and safety of biologic agents for psoriasis treatment are limited. OBJECTIVE: To evaluate long-term tildrakizumab efficacy, drug survival, and safety in patients with psoriasis by baseline MetS status. METHODS: Post hoc analyses of up to 3 years of efficacy data and 5 years of safety data from the phase 3, double-blind, randomized controlled reSURFACE 1 and 2 trial (NCT01722331 and NCT01729754) base and extension studies were conducted for patients receiving continuous tildrakizumab 100 or 200 mg. RESULTS: Of 338 (n = 124/214 in reSURFACE 1/2) and 307 (n = 147/160 in reSURFACE 1/2) patients continuously receiving tildrakizumab 100 and 200 mg, respectively, throughout the studies, 26/44 (21%/21%) and 34/30 (23%/19%) met MetS criteria. Proportions of patients who achieved a 75% improvement in the Psoriasis Area and Severity Index (PASI) in reSURFACE 1/2 were generally comparable among those with versus without MetS at week 52 (tildrakizumab 100 mg, 85%/86% vs 86%/94%; tildrakizumab 200 mg, 76%/87% vs 76%/87%) and through week 148. Results were similar for responders with 90% and 100% improvement in the PASI. Tildrakizumab's safety profile did not vary by MetS status. LIMITATIONS: Small sample size and post hoc analysis limit interpretation. CONCLUSION: Long-term tildrakizumab efficacy and safety were comparable between patients with and without MetS.
引用
- Lebwohl MG, Leonardi CL, Mehta NN, et al. Tildrakizumab efficacy, drug survival, and safety are comparable in patients with psoriasis with and without metabolic syndrome: Long-term results from 2 phase 3 randomized controlled studies (reSURFACE 1 and reSURFACE 2). J Am Acad Dermatol. 2020. PMID: 32961255. doi:10.1016/j.jaad.2020.09.047
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。